GT201700189A - Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos - Google Patents

Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos

Info

Publication number
GT201700189A
GT201700189A GT201700189A GT201700189A GT201700189A GT 201700189 A GT201700189 A GT 201700189A GT 201700189 A GT201700189 A GT 201700189A GT 201700189 A GT201700189 A GT 201700189A GT 201700189 A GT201700189 A GT 201700189A
Authority
GT
Guatemala
Prior art keywords
nucleosids
derivatives
antineoplastic agents
replaced
useful
Prior art date
Application number
GT201700189A
Other languages
English (en)
Inventor
John Howard Tatlock
Indrawan James Mcalpine
Michelle Bich Tran-Dube
Eugene Yuanjin Rui
Martin James Wythes
Robert Arnold Kumpf
Michele Ann Mctigue
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of GT201700189A publication Critical patent/GT201700189A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom

Abstract

LOS COMPUESTOS DE FÓRMULA GENERAL (I): PROCESOS PARA LA PREPARACIÓN DE ESTOS COMPUESTOS, COMPOSICIONES QUE CONTIENEN ESTOS COMPUESTOS Y LOS USOS DE ESTOS COMPUESTOS.
GT201700189A 2015-02-24 2017-08-24 Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos GT201700189A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562119932P 2015-02-24 2015-02-24
US201562213801P 2015-09-03 2015-09-03
US201662279209P 2016-01-15 2016-01-15

Publications (1)

Publication Number Publication Date
GT201700189A true GT201700189A (es) 2019-06-10

Family

ID=55451515

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201700189A GT201700189A (es) 2015-02-24 2017-08-24 Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos

Country Status (29)

Country Link
US (1) US10428104B2 (es)
EP (1) EP3262057B1 (es)
JP (1) JP6584521B2 (es)
KR (1) KR20170119705A (es)
CN (1) CN107278205A (es)
AU (2) AU2016225133B2 (es)
BR (1) BR112017017396A2 (es)
CA (1) CA2921314A1 (es)
CL (1) CL2017002155A1 (es)
CO (1) CO2017008403A2 (es)
CR (1) CR20170384A (es)
CU (1) CU20170105A7 (es)
DO (1) DOP2017000195A (es)
EA (1) EA031895B1 (es)
ES (1) ES2792899T3 (es)
GT (1) GT201700189A (es)
IL (1) IL253637A0 (es)
MX (1) MX2017010844A (es)
NI (1) NI201700095A (es)
PE (1) PE20171449A1 (es)
PH (1) PH12017501413A1 (es)
SG (1) SG11201706050WA (es)
SV (1) SV2017005514A (es)
TN (1) TN2017000357A1 (es)
TW (1) TWI622595B (es)
UA (1) UA118315C2 (es)
UY (1) UY36564A (es)
WO (1) WO2016135582A1 (es)
ZA (1) ZA201705092B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR104326A1 (es) 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
TW202321249A (zh) 2015-08-26 2023-06-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６－６雙環芳香環取代之核苷類似物
EA201892031A1 (ru) 2016-03-10 2019-02-28 Янссен Фармацевтика Нв Замещенные аналоги нуклеозидов для применения в качестве ингибиторов prmt5
WO2017153186A1 (en) 2016-03-10 2017-09-14 Janssen Pharmaceutica Nv Substituted nucleoside analogues for use as prmt5 inhibitors
MA46228A (fr) 2016-09-14 2019-07-24 Janssen Pharmaceutica Nv Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll
CN109689663B (zh) 2016-09-14 2023-04-14 詹森药业有限公司 Menin-mll相互作用的螺二环抑制剂
MX2019003843A (es) * 2016-10-03 2019-06-24 Janssen Pharmaceutica Nv Análogos novedosos de carbanucleósidos sustituidos de sistema anular monocíclico y bicíclico para su uso como inhibidores de prmt5.
US10745409B2 (en) 2016-12-15 2020-08-18 Janssen Pharmaceutica Nv Azepane inhibitors of menin-MLL interaction
WO2018152501A1 (en) * 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018152548A1 (en) * 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
EA201990851A1 (ru) 2017-02-24 2019-09-30 Янссен Фармацевтика Нв Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
UA127679C2 (uk) 2017-02-27 2023-11-29 Янссен Фармацевтика Нв Спосіб ідентифікації пацієнта, що характеризується наявністю сприйнятливості до лікування недрібноклітинного раку легені інгібітором prmt5
WO2018160855A1 (en) 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
EP3665179B1 (en) 2017-08-09 2021-06-09 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
CN111542525B (zh) * 2017-10-26 2023-06-27 普莱鲁德疗法有限公司 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂
CA3084449A1 (en) 2017-12-08 2019-06-13 Janssen Pharmaceutica Nv Novel spirobicyclic analogues
HUE059945T2 (hu) 2017-12-13 2023-01-28 Lupin Ltd Helyettesített biciklusos heterociklusos vegyületek, mint PRMT5 inhibitorok
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
BR112020018636A2 (pt) 2018-03-14 2020-12-29 Prelude Therapeutics, Incorporated Inibidores seletivos de proteína arginina metiltransferase 5 (prmt5)
US10711007B2 (en) 2018-03-14 2020-07-14 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
US20210309687A1 (en) * 2018-08-07 2021-10-07 Merck Sharp & Dohme Corp. Prmt5 inhibitors
AU2020223058A1 (en) * 2019-02-13 2021-09-09 Prelude Therapeutics, Incorporated Selective inhibitor of protein arginine methyltransferase 5 (PRMT5)
KR20220023330A (ko) * 2019-03-25 2022-03-02 캘리포니아 인스티튜트 오브 테크놀로지 Prmt5 억제제 및 이의 용도
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用ｐｒｍｔ５抑制劑治療癌症之方法
LT3980417T (lt) 2019-06-10 2023-12-27 Lupin Limited Prmt5 inhibitoriai
PE20220433A1 (es) 2019-06-12 2022-03-29 Janssen Pharmaceutica Nv Intermedios espirobiciclicos novedosos
CN114599361A (zh) 2019-10-22 2022-06-07 印度鲁宾有限公司 Prmt5抑制剂的药物组合物
CN115135651A (zh) 2019-12-03 2022-09-30 鲁皮恩有限公司 作为prmt5抑制剂的被取代的核苷类似物
MX2023002037A (es) 2020-08-18 2023-06-12 Incyte Corp Proceso e intermediarios para preparar un inhibidor de las cinasas de janus (jak).
EP4200278A1 (en) 2020-08-18 2023-06-28 Incyte Corporation Process and intermediates for preparing a jak1 inhibitor
WO2022074391A1 (en) * 2020-10-08 2022-04-14 Storm Therapeutics Limited Compounds inhibitors of mettl3
CN112679505B (zh) * 2020-12-25 2022-04-22 杭州澳赛诺生物科技有限公司 一种4-甲基-7H-吡咯并[2,3-d]嘧啶的合成方法
WO2022153161A1 (en) 2021-01-14 2022-07-21 Pfizer Inc. Treatment of cancer using a prmt5 inhibitor
WO2023017152A1 (en) * 2021-08-13 2023-02-16 Albert-Ludwigs-Universität Freiburg Specific small molecule inhibitors that block kmt9 methyltransferase activity and function

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5864033A (en) * 1989-09-15 1999-01-26 Metabasis Therapeutics, Inc. Adenosine kinase inhibitors
US5795977A (en) * 1989-09-15 1998-08-18 Metabasis Therapeutics, Inc. Water soluble adenosine kinase inhibitors
US5646128A (en) * 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
GB9813554D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
US6831069B2 (en) * 1999-08-27 2004-12-14 Ribapharm Inc. Pyrrolo[2,3-d]pyrimidine nucleoside analogs
CA2495370A1 (en) * 2002-08-15 2004-02-26 Cv Therapeutics, Inc. Partial and full agonists of a1 adenosine receptors
AU2010226466A1 (en) * 2009-03-20 2011-10-20 Alios Biopharma, Inc. Substituted nucleoside and nucleotide analogs
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
US9416154B2 (en) * 2011-07-13 2016-08-16 Merck Sharp & Dohme Corp. 5′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2013044030A1 (en) * 2011-09-23 2013-03-28 Enanta Pharmaceuticals, Inc. 2'-chloroacetylenyl substituted nucleoside derivatives
US20170198006A1 (en) * 2014-06-25 2017-07-13 Epizyme, Inc. Prmt5 inhibitors and uses thereof
AR104326A1 (es) * 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
AU2016301188A1 (en) * 2015-08-06 2018-02-15 Chimerix, Inc. Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents

Also Published As

Publication number Publication date
TWI622595B (zh) 2018-05-01
KR20170119705A (ko) 2017-10-27
PE20171449A1 (es) 2017-10-02
JP2018510850A (ja) 2018-04-19
BR112017017396A2 (pt) 2018-04-03
CL2017002155A1 (es) 2018-05-11
MX2017010844A (es) 2017-12-07
EA201791563A1 (ru) 2018-01-31
EA031895B1 (ru) 2019-03-29
CO2017008403A2 (es) 2017-10-31
CU20170105A7 (es) 2017-10-05
EP3262057A1 (en) 2018-01-03
EP3262057B1 (en) 2020-04-15
WO2016135582A1 (en) 2016-09-01
SG11201706050WA (en) 2017-09-28
ZA201705092B (en) 2019-06-26
IL253637A0 (en) 2017-09-28
CR20170384A (es) 2017-11-16
AU2016225133A1 (en) 2017-08-10
CA2921314A1 (en) 2016-08-24
TN2017000357A1 (en) 2019-01-16
CN107278205A (zh) 2017-10-20
US20160244475A1 (en) 2016-08-25
TW201643176A (zh) 2016-12-16
DOP2017000195A (es) 2017-10-15
SV2017005514A (es) 2018-04-11
JP6584521B2 (ja) 2019-10-02
AU2018278842A1 (en) 2019-01-03
AU2016225133B2 (en) 2018-11-29
UY36564A (es) 2016-09-30
NI201700095A (es) 2017-10-31
UA118315C2 (uk) 2018-12-26
US10428104B2 (en) 2019-10-01
PH12017501413A1 (en) 2018-01-29
ES2792899T3 (es) 2020-11-12

Similar Documents

Publication Publication Date Title
GT201700189A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
CO2018013105A2 (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
UY38070A (es) Derivados de quinazolina y piridopirimidina sustituidos útiles como agentes anticáncer
CL2018000730A1 (es) Compuestos heterocíclicos y usos de los mismos
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
DOP2018000270A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
CR20170564A (es) Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
CR20180072A (es) Nuevos compuestos biciclicos como inhibidores de atx
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
CU20180027A7 (es) DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA, ÚTILES COMO INHIBIDORES DOBLES DE DYRK 11CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
CO2019012767A2 (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo
CO2018004581A2 (es) Compuestos de criptoficina y productos conjugados, y sus métodos de preparación
ECSP17069696A (es) Compuestos novedosos
CL2016002089A1 (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CL2017000151A1 (es) Derivados de piridona
CR20180181A (es) Nuevos derivados de imidazol[4,5-b]piridina, un proceso para su preparación y composiciones farmacéuticas que los contienen
ECSP17063489A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
CR20140051A (es) Compuestos de tiazol y oxazol de bencen-sulfonamida